Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE

Next Previous
X
Search
Trial Profile

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crenezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CREAD2
  • Sponsors Chugai Pharmaceutical; Roche

    • Most Recent Events

    • 20 Jul 2023 Results from CREAD, CREAD2 and Tauriel; assessing assess the additive prognostic value of including baseline [18F]GTP1 tau-PET with the other common predictors presented at the Alzheimer's Association International Conference 2023.
    • 27 Apr 2023 Results of pooled post hoc analysis assessing utility of plasma neurofilament light chain (pNfL) as a biomarker of neurodegenerative diseases using a fixed threshold for screening in clinical practice from (NCT03664804, NCT03664804, NCT03100149, NCT01194570) presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 09 Nov 2022 Results from CREAD, CREAD2 and Tauriel; assessing independence in activities of daily living in People With Early Alzheimers Disease, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top